SEARCH:   Advanced

Blood, 15 August 2005, Vol. 106, No. 4, pp. 1341-1345. Prepublished online as a Blood First Edition Paper on May 10, 2005; DOI 10.1182/blood-2004-11-4477. This Article Full Text Full Text (PDF) All Versions of this Article: 2004-11-4477v1 106/4/1341    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Tassone, P. Articles by Munshi, N. C. Search for Related Content PubMed PubMed Citation Articles by Tassone, P. Articles by Munshi, N. C. Related Collections Immunobiology Neoplasia Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA A SCID-hu in vivo model of human Waldenström macroglobulinemia Pierfrancesco Tassone, Paola Neri, Jeffery L. Kutok, Olivier Tournilhac, Daniel Ditzel Santos, Evdoxia Hatjiharissi, Vidit Munshi, Salvatore Venuta, Kenneth C. Anderson, Steven P. Treon, and Nikhil C. Munshi From the Dana-Farber Cancer Institute, Boston, MA; the Veteran's Administration (VA) Boston Healthcare System, Boston, MA; the Brigham and Woman's Hospital, Harvard Medical School, Boston, MA; and the University of Magna Græcia and Cancer Center, Catanzaro, Italy. The preclinical evaluation of investigational agents for Waldenström macroglobulinemia (WM) has been limited by the lack of in vivo models that enable the use of explanted patient cells. We describe here a novel in vivo model of human WM in severe combined immunodeficient (SCID) mice implanted with human fetal bone chips (SCID-hu mice) into which WM cells from patient bone marrow are engrafted directly into the human bone marrow (huBM) microenvironment. WM cells in SCID-hu mice produced human monoclonal paraprotein (immunoglobulin M [IgM] and/or or chain) detectable in mice sera. Immunohistochemical analysis of human bone retrieved from SCID-hu mice showed infiltration with CD20+, IgM+, and monotypic light chain+ lymphoplasmacytic cells. Mast cells were observed to be associated with the infiltrate in these sections. Treatment of SCID-hu mice bearing WM with rituximab induced tumor regression, associated with a decrease in serum paraprotein. This model, therefore, recapitulates the in vivo biology of WM and allows the study of novel investigational drugs targeting WM cells in the huBM milieu. (Blood. 2005;106:1341-1345) CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: A "not so micro" model for a "macro" problem Rafael Fonseca Blood 2005 106: 1143-1144. [Full Text] [PDF] This article has been cited by other articles: A. W. Ho, E. Hatjiharissi, B. T. Ciccarelli, A. R. Branagan, Z. R. Hunter, X. Leleu, O. Tournilhac, L. Xu, K. O'Connor, R. J. Manning, et al. CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia Blood, December 1, 2008; 112(12): 4683 - 4689. [Abstract] [Full Text] [PDF] A.-S. Moreau, X. Jia, H. T. Ngo, X. Leleu, G. O'Sullivan, Y. Alsayed, A. Leontovich, K. Podar, J. Kutok, J. Daley, et al. Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia Blood, June 1, 2007; 109(11): 4964 - 4972. [Abstract] [Full Text] [PDF] W. Dalton and K. C. Anderson Synopsis of a Roundtable on Validating Novel Therapeutics for Multiple Myeloma. Clin. Cancer Res., November 15, 2006; 12(22): 6603 - 6610. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020